In addition, one study suggested that hepatic six transmembrane protein of prostate 2 may be the downstream therapeutic target of FGF21 to improve NAFLD accompanying hepatic iron overload 188. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.